Start Date
June 30, 2019
Primary Completion Date
February 28, 2021
Study Completion Date
February 28, 2026
Idelalisib
Tablet (s) or dispersible tablets for suspension administered orally twice daily
Rituximab
375 mg/m\^2 administered intravenously
Ifosfamide
3 mg/m\^2 administered intravenously
Carboplatin
635 mg/m\^2 administered intravenously
Etoposide
100 mg/m\^2 administered intravenously
Infantile Regina Margherita Hospital, Torino
Istituto Giannina Gaslini, Genova
Hospital Universitario HM Monteprincipe, Madrid
Centre Hospitalier Régional Universitaire de Lille, Lille
Ospedale Pediatrico Bambino Gesu, Roma
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw
Hospital Vall d´Hebrón, Barcelona
Lead Sponsor
Gilead Sciences
INDUSTRY